Targeted Therapies in Thyroid Cancer
Fig. 11.1 MAPK pathway, TKI receptor inhibition MAPK mitogen-activated protein kinase TK tyrosine kinase Fifty per cent of cases of sporadic MTC result from somatic mutations in the RET gene….
Fig. 11.1 MAPK pathway, TKI receptor inhibition MAPK mitogen-activated protein kinase TK tyrosine kinase Fifty per cent of cases of sporadic MTC result from somatic mutations in the RET gene….
ATA [8] Over age of 45 years with grossly visible extrathyroidal extension at the time of surgery and a high likelihood of microscopic residual disease Gross residual tumour for whom…
59. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer….
Fig. 2.1 Neck levels and their relation to the accessory nerve Table 2.1 Incidence and distribution of lymph node metastases by level in patients undergoing a therapeutic lateral neck dissection…
Series Levels dissected Sivanandan and Soo (2001) [37] II–IV Pingpank et al. (2002) [38] II–V Caron et al. (2006) [34] III, IV Yanir and Doweck (2008) [39] II–V Kupferman et…
Author/Year Study information RLN palsy Hypocalcaemia Transient (%) Permanent (%) Transient (%) Permanent (%) Shah et al. (2012) [42] 82 pts retrospective review 2 2 20 7 Clayman et al….
© K. Alok Pathak, Richard W. Nason, Janice L. Pasieka, Rehan Kazi, Raghav C. Dwivedi 2015K. Alok Pathak, Richard W. Nason and Janice L. Pasieka (eds.)Management of Thyroid CancerHead and Neck Cancer Clinics10.1007/978-81-322-2434-1_9 9. Anaplastic Thyroid…
45. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.PubMedCrossRef 46. Schlumberger M. Target therapies for radioiodine…
Fig. 8.1 Dissection is performed deep to Buck’s fascia 3. Control of dorsal venous complex. 4. Dissection between urethra and corporal bodies without dividing the urethra. 5….
T Primary tumor TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ Ta Noninvasive verrucous carcinoma, not associated with destructive invasion T1 Tumor…